Work

Adjuvant Therapy in Resected Adrenocortical Carcinoma: Current Evidence and Patient Selection

Year: 2026

Type: review

Abstract: Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with recurrence rates of 54-70% following curative-intent resection, even after microscopically complete (R0) surgery. In this review, we summarize the current evidence for adjuvant mitotane, platinum-based chemotherapy, and radiation therapy in resected ACC, and discuss patient selection based on prognostic risk stratification. We also highlight the importance of multidisciplinary management at expert centers, remaining evidence gaps, and future directions including biomarker-driven treatment strategies.

Source: Cancers

DOI: 10.3390/cancers18203276

Authors: Lina Pedraza Sanchez, Guilherme Rabinowits, Elio Monsour, Prerna Dogra

Institution: Moffitt Cancer Center

Language: English

Topic: Adrenal and Paraganglionic Tumors

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,499